UK-based specials manufacturer Quantum Pharmaceutical has appointed Andrew Matthews as operations director to maintain high performance standards and develop the business.
Matthews has more than 12 years’ experience in the pharmaceutical and healthcare industries. He has specialist knowledge in product areas for sterile and non-sterile medicines.
Matthews’ experience in quality driven operations management for unlicensed and licensed medicines will assist Quantum Pharmaceutical in its aim of strengthening links with hospitals, care home and home care pharmaceutical providers, as the company broadens its core customer base.
‘Andrew had an excellent CV and great track record as head of manufacturing ‘Specials’ with his former employer, domiciliary care organisation Healthcare At Home,’ said Andy Scaife, md of Quantum Pharmaceutical.
‘With knowledge of this niche sector of the pharmaceutical industry, Andrew is an excellent fit for Quantum but, most importantly, he brings a new skills set which will be of great benefit as we look to exploit new market opportunities.
Quantum Pharmaceutical appoints operations director
Andrew Matthews brings a new set of skills to the company
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From bespoke to scalable: closing the manufacturing gap in advanced therapeutics
Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics